Preanalytical variables and Alzheimer disease biomarker concentrations in cerebrospinal fluid

Clinical Chemistry

Volumn 61, Issue 5, 2015, Pages 686-688

  Florkowski, Christopher M ^a  

^a CANTERBURY HEALTH LABORATORIES   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; TAU PROTEIN; BIOLOGICAL MARKER;

ALZHEIMER DISEASE; BRAIN TISSUE; CEREBROSPINAL FLUID; EDITORIAL; FREEZE THAWING; FREEZING; HUMAN;

ALZHEIMER DISEASE; BIOLOGICAL MARKERS; HUMANS;

EID: 84929001617     PISSN: 00099147     EISSN: 15308561     Source Type: Journal    
DOI: 10.1373/clinchem.2015.240069     Document Type: Editorial

References (14)

1. Seppala TT, Nerg O, Koivisto AM, Rummukainen J, Puli L, Zetterberg H, et al. CSF biomarkers for Alzheimer disease correlate with cortical brain biopsy findings. Neurology 2012;78:1568-75.
2. Moghekar A, Li S, Lu Y, Li M, Wang MC, Albert M, et al. CSF biomarker changes precede symptom onset of mild cognitive impairment. Neurology 2013;81:1753-8.
3. Mattsson N, Zetterberg H, Hansson O, Andreasen N, Parnetti L, Jonsson M, et al. CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. JAMA 2009;302:385-93.
4. Blennow K, Hampel H, Weiner M, Zetterberg H. Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat Rev Neurol 2010;6:131-44.
5. Bian H, Van Swieten JC, Leight S, Massimo L, Wood E, Forman M, et al. CSF biomarkers in frontotemporal lobar degeneration with known pathology. Neurology 2008;70:1827-35.
6. Dubois B, Feldman HH, Jacova C, Hampel H, Molinuevo JL, Blennow K, et al. Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria. Lancet Neurol 2014;13:614-29.
7. Slaets S, Le Bastard N, Theuns J, Sleegers K, Verstraeten A, De Leenheir E, et al. Amyloid pathology influences abeta1-42 cerebrospinal fluid levels in dementia with lewy bodies. J Alzheimers Dis 2013;35:137-46.
8. Le Bastard N, De Deyn PP, Engelborghs S. Importance and impact of preanalytical variables on Alzheimer disease biomarker concentrations in cerebrospinal fluid. Clin Chem 2015;61:734-43.
9. Bjerke M, Portelius E, Minthon L, Wallin A, Anckarsater H, Anckarsater R, et al. Confounding factors influencing amyloid beta concentration in cerebrospinal fluid. IntJ Alzheimers Dis 2010;2010:986310.
10. Vanderstichele H, Bibl M, Engelborghs S, Le Bastard N, Lewczuk P, Molinuevo JL, et al. Standardization of preanalytical aspects of cerebrospinal fluid biomarker testing for Alzheimer's disease diagnosis: a consensus paper from the Alzheimer's Biomarkers Standardization Initiative. Alzheimers Dement 2012;8:65-73.
11. Andreasen N, Hesse C, Davidsson P, Minthon L, Wallin A, Winblad B, et al. Cerebrospinal fluid beta-amyloid (1-42) in Alzheimer disease: differences between early-and late-onset Alzheimer disease and stability during the course of disease. Arch Neurol 1999;56:673-80.
12. Mattsson N, Andreasson U, Persson S, Carrillo MC, Collins S, Chalbot S, et al. CSF biomarker variability in the Alzheimer's Association quality control program. Alzheimers Dement 2013;9:251-61.
13. Lundberg GD. Acting on significant laboratory results. JAMA 1981;245:1762-3.
14. Plebani M, Sciacovelli L, Aita A, Chiozza ML. Harmonization of pre-analytical quality indicators. Biochem Med 2014;24:105-13.